IMAX Corp Chief Executive Officer Richard L. Gelfond filed a Form 4 on August 20, 2026, disclosing the exercise of stock options and subsequent sale of common shares across three trading days under a pre-established 10b5-1 plan.

Key Highlights

  • Option exercises: Gelfond converted 151,253 stock options on August 18, 2026, and 205,504 stock options on August 19, 2026, at an exercise price of $31.9 per share.
  • Share sales: 151,253 shares were sold on August 18, 2026, at $51.0049, and 205,504 shares were sold on August 19, 2026, at $53.2656, both pursuant to the 10b5-1 plan.
  • Additional sale: 100,000 common shares were sold directly on August 20, 2026, at $53.2337 per share.
  • Remaining balances: Following all transactions, Gelfond held 665,002 common shares directly, 975,654 remaining outstanding options, and 231,562 restricted share units, according to the filing.
  • Options origin: The exercised options were issued in 2017 and are set to expire on January 3, 2027.
  • 10b5-1 plan: The exercises and corresponding sales were made pursuant to a 10b5-1 plan dated May 19, 2026.

IMAX CEO Stock Option Exercises and Share Sales Under Pre-Planned Program

According to the Form 4 filed with the SEC, Richard L. Gelfond, who serves as both a Director and Chief Executive Officer of IMAX Corp (NYSE:IMAX), reported a series of transactions in the company's common shares between August 18 and August 20, 2026. The filing indicates all transactions were conducted under a Rule 10b5-1(c) plan established on May 19, 2026.

On August 18 and 19, 2026, Gelfond exercised a combined 356,757 stock options (transaction code C) at a conversion price of $31.9 per share, converting them into an equivalent number of common shares. The filing states these options were issued in 2017 and are scheduled to expire on January 3, 2027. The options became exercisable across nine installments beginning May 1, 2017, with individual tranche amounts of either 39,640 or 39,639 shares. On each of those same dates, the acquired common shares were sold: 151,253 shares at $51.0049 on August 18, and 205,504 shares at $53.2656 on August 19. An additional 100,000 common shares were sold on August 20, 2026, at $53.2337 per share.

The filing discloses that following all reported transactions, Gelfond's aggregate balances are 975,654 remaining outstanding options, 231,562 restricted share units, and 665,002 directly held common shares. The opening balance of common shares before the reported transactions was listed as 765,002, which returned to that level after each option-exercise-and-sale pair before declining to 665,002 following the August 20 sale.

What Was Disclosed

The filing reports that IMAX CEO Richard Gelfond exercised 356,757 stock options and sold a total of 456,757 common shares between August 18 and August 20, 2026, under a pre-established 10b5-1 plan, retaining 665,002 directly held common shares afterward.